IMPE Abstracts

Introduction: Gonadotropin-releasing hormone agonists (GnRHa) have been a gold standard treatment for central precocious puberty (CPP) for last 30 years. However, it is still controversial over the adverse reactions that may occur during the treatment. Especially, GnRHa treatment can reduce bone mineral density (BMD) by increasing bone turnover and suppressing of gonadal hormone. Therefore, for evaulating the effect of GnRHa on BMD, we measured serial BMD before and after GnRHa treatment in CPP patients.

Methods: We enrolled 19 female CPP patients and measured BMD using dual-energy X-ray absorptiometry (DXA) before and after their GnRHa treatment. The initial and final BMD of total body (BMDTB) and total body less head (BMDTBLH) were measured, and the results were corrected according to chronological age (CA) and bone age (BA).

Results: The average treatment start age was 8.5±0.4 years old, and the average age at the end of treatment was 10.3±0.4 years old. Average treatment duration was 1.8±0.6 years. Initial BMDTB was 0.839±0.036 g/cm3 and BMDTBLH was 0.721±0.043 g/cm3. At near final height after menarche, final BMDTB was 1.025±0.062 g/cm3 and BMDTBLH was 0.915±0.64 g/cm3. The absolute value of the BMD was increased (P<0.05). When the BMD SDS value was corrected to CA, SDSTB was increased after treatment (P=0.001), and there was no difference in SDSTBLH (P=0.272). On the contrary, comparing the SDS values according to the BA which represents biological maturation age, no significant change was observed (P=0.564 (SDSTB), P=0.142 (SDSTBLH)).

Conclusions: According to our results, absolute value of BMD of female CPP patients treated with GnRHa increased after treatment but showed no obvious difference when comparing SDS assessed based on BA.